In April 2013, the American College of Medical Genetics (ACMG) recommended that clinical
laboratories conducting whole genome sequencing (WGS) and whole exome sequencing (WES) for specific
clinical indications should also analyze and report any mutations identified from a list of 57 genes
considered medically actionable, regardless of whether patients wish to receive the results.1 These recommendations have sparked a heated debate with profound
implications for countless physicians and their patients.
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 12
Customize your page view by dragging & repositioning the boxes below.
More Listings atJAMACareerCenter.com >
All results at
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.